deoxyepinephrine has been researched along with Glaucoma in 4 studies
Deoxyepinephrine: Sympathomimetic, vasoconstrictor agent.
Glaucoma: An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "An ibopamine challenge is a novel technique for assessing glaucoma using ibopamine, a topical drug which temporarily increases aqueous production." | 9.20 | Ibopamine challenge testing differentiates glaucoma suspect, stable glaucoma and progressive glaucoma cases. ( Craig, JE; Landers, J; Ullrich, K, 2015) |
| "Ibopamine 2% eye drops have a positive pressure effect in 50% of suspected normal-tension glaucoma eyes and may differentiate between eyes with normal trabecular outflow capacity and eyes with increased resistance in the trabecular meshwork that are prone to pressure peaks and deterioration to glaucoma." | 7.74 | [Positive ibopamine provocative test in normal-tension glaucoma suspects]. ( Gloor, BP; Kniestedt, C; Romppainen, T; Stürmer, J, 2007) |
| "A glaucoma patient with a positive ibopamine challenge will show a negative challenge result when re-tested following trabeculectomy surgery." | 5.22 | Ibopamine challenge testing becomes negative following successful trabeculectomy surgery. ( Craig, JE; Landers, J; Ullrich, K, 2016) |
| "An ibopamine challenge is a novel technique for assessing glaucoma using ibopamine, a topical drug which temporarily increases aqueous production." | 5.20 | Ibopamine challenge testing differentiates glaucoma suspect, stable glaucoma and progressive glaucoma cases. ( Craig, JE; Landers, J; Ullrich, K, 2015) |
| "Ibopamine 2% eye drops have a positive pressure effect in 50% of suspected normal-tension glaucoma eyes and may differentiate between eyes with normal trabecular outflow capacity and eyes with increased resistance in the trabecular meshwork that are prone to pressure peaks and deterioration to glaucoma." | 3.74 | [Positive ibopamine provocative test in normal-tension glaucoma suspects]. ( Gloor, BP; Kniestedt, C; Romppainen, T; Stürmer, J, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Landers, J | 2 |
| Ullrich, K | 2 |
| Craig, JE | 2 |
| Kniestedt, C | 1 |
| Romppainen, T | 1 |
| Gloor, BP | 1 |
| Stürmer, J | 1 |
| Taverniti, L | 1 |
| Di Staso, S | 1 |
| Arrico, L | 1 |
| D'Ubaldo, E | 1 |
| Grenga, R | 1 |
2 trials available for deoxyepinephrine and Glaucoma
| Article | Year |
|---|---|
Ibopamine challenge testing differentiates glaucoma suspect, stable glaucoma and progressive glaucoma cases.
Topics: Aged; Aged, 80 and over; Deoxyepinephrine; Disease Progression; Dopamine Agonists; Female; Glaucoma; | 2015 |
Ibopamine challenge testing becomes negative following successful trabeculectomy surgery.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Deoxyepinephrine; Disease Progression; Dopamine Ag | 2016 |
2 other studies available for deoxyepinephrine and Glaucoma
| Article | Year |
|---|---|
[Positive ibopamine provocative test in normal-tension glaucoma suspects].
Topics: Deoxyepinephrine; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Mydriatics; Rep | 2007 |
The ibopamine test in patients affected by monolateral pseudoexfoliative glaucoma.
Topics: Aqueous Humor; Deoxyepinephrine; Dopamine Agonists; Exfoliation Syndrome; Glaucoma; Humans; Intraocu | 2000 |